The Serum Institute of India said it plans this year to produce up to 60 million doses of a potential vaccine against the novel coronavirus that is being developed by researchers at Oxford Univerisy, as reported in the National Post.
While the vaccine, dubbed ChAdOx1 nCoV-19, is yet to be proven to work against COVID-19, Serum decided to start manufacturing it as it had shown success in animal trials and had progressed to clinical testing, according to CEO Adar Poonawalla.
Poonawalla said he hoped trials of the Oxford vaccine, due to finish in about September, would be successful.
He added that Serum plans to make the vaccine at its two manufacturing plants in the western Indian city of Pune, aiming to produce up to 400 million doses next year if all goes well.
Serum has also partnered with the Codagenix and Themis on two other COVID-19 vaccine candidates and plans to announce a fourth alliance in a couple of weeks, he said.
To read more NewsPoints articles, click here.